Importance of NT-proBNP and conventional risk factors for prediction of death in older adults with and without diabetes mellitus- A report from the Atherosclerosis Risk in Communities (ARIC) study.Show others and affiliations
2022 (English)In: Diabetes Research and Clinical Practice, ISSN 0168-8227, E-ISSN 1872-8227, Vol. 194, article id 110164Article in journal (Refereed) Published
Abstract [en]
In this community-based cohort of 5861 individuals followed for median 7.2 years, the discriminatory ability of NT-proBNP alone in predicting mortality was similar to that of multiple conventional markers of risk in people without diabetes. In people with diabetes, NT-proBNP alone discriminated risk of mortality better than conventional risk factors.
Place, publisher, year, edition, pages
Elsevier, 2022. Vol. 194, article id 110164
Keywords [en]
B-type natriuretic peptide, Biomarkers, Diabetes mellitus, Epidemiology, Mortality, Risk prediction
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:liu:diva-192637DOI: 10.1016/j.diabres.2022.110164ISI: 001010866400010PubMedID: 36410558OAI: oai:DiVA.org:liu-192637DiVA, id: diva2:1746023
Note
Funding: National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services [HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I, R01 HL-134320]; Swedish Heart Association; Swedish Society of Medicine; Region Ostergotland, Sweden; Lilly; Rubin Medical; Sanofi; Novartis; Novo Nordisk; Bayer AG; Galmed; Occlutech; Impulse Dynamics; Actelion; Alnylam; Amgen; AstraZeneca; Bellerophon; Bayer; BMS; Celladon; Cytokinetics; Eidos; Gilead; GSK; Ionis; Mesoblast; MyoKardia; NIH/NHLBI; Neurotronik; NovoNordisk; Respicardia; Sanofi Pasteur; Theracos; US2.AI
2023-03-272023-03-272023-09-01